PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma
Perioperative Stromal Depletion Strategies in Pancreatic Ductal Adenocarcinoma
Sponsor: Andrew Ko
Terminated
Low accrual
Other terminated trials from Andrew Ko
More terminations from Andrew Ko
A PHASE2 clinical study on Adenocarcinoma, this trial is terminated or withdrawn. The trial is conducted by Andrew Ko and has accumulated 11 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Feb 2020 — Jan 2021 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jun 2018 — Feb 2020 [monthly]
Recruiting PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jul 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Jul 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Andrew Ko
For direct contact, visit the study record on ClinicalTrials.gov .